Nabriva Therapeutics AG (NASDAQ:NBRV)’s share price traded down 0.1% during trading on Wednesday . The stock traded as low as $6.51 and last traded at $6.67. 213,937 shares were traded during trading, a decline of 71% from the average session volume of 738,977 shares. The stock had previously closed at $6.66.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a report on Wednesday, October 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price (up from $15.00) on shares of Nabriva Therapeutics AG in a report on Tuesday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Nabriva Therapeutics AG in a report on Tuesday, September 19th. Wedbush reaffirmed an “outperform” rating and set a $21.00 target price (up from $13.00) on shares of Nabriva Therapeutics AG in a report on Monday, September 18th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $22.00 target price (up from $20.00) on shares of Nabriva Therapeutics AG in a report on Monday, September 18th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $18.78.

The firm’s market capitalization is $179.55 million. The stock has a 50-day moving average of $8.37 and a 200 day moving average of $9.76.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million. Analysts anticipate that Nabriva Therapeutics AG will post ($2.29) EPS for the current year.

In other news, major shareholder Hbm Healthcare Investments (Ca sold 6,585 shares of the firm’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $10.51, for a total transaction of $69,208.35. Following the completion of the sale, the insider now owns 2,391,177 shares of the company’s stock, valued at $25,131,270.27. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were purchased at an average cost of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 57,219 shares of company stock valued at $535,919 and have sold 125,816 shares valued at $1,249,475. Company insiders own 2.75% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of NBRV. Almanack Investment Partners LLC. increased its holdings in shares of Nabriva Therapeutics AG by 482.2% during the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after buying an additional 751,366 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Nabriva Therapeutics AG by 9.9% during the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Nabriva Therapeutics AG by 19.6% during the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after buying an additional 8,650 shares in the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Nabriva Therapeutics AG by 4.6% during the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after buying an additional 7,924 shares in the last quarter. 50.23% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.watchlistnews.com/nabriva-therapeutics-ag-nbrv-trading-down-0-1/1639433.html.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.